Social media

Flexible, risk-based monitoring strategies are transforming global trial delivery. ICON’s new whitepaper shows how smarter oversight improves quality, reduces cost and accelerates timelines. Download now: https://www.ico...

Flexible, risk-based monitoring strategies are transforming global trial delivery. ICON’s new whitepaper shows how smarter oversight improves quality, reduces cost and accelerates timelines. Download now: https://lnkd.in...

Early clinical trial designs—especially first-in-human (FIH) studies—are increasingly tailored to the unique needs of specific therapeutic areas. In neurodegenerative diseases, there is a growing shift toward flexible an...

Early clinical trial designs—especially first-in-human (FIH) studies—are increasingly tailored to the unique needs of specific therapeutic areas. In neurodegenerative diseases, there is a growing shift toward flexible an...

In the dynamic world of life sciences, the consultancy sector is undergoing a transformation as cost pressures increase, speed to market needs accelerate and technology permeates every aspect. Against this backdrop, clie...

Customer advocacy is not a trend, it’s a transformation. It represents a shift from service to stewardship and from expertise to empathy. It’s about recognising that behind every clinical milestone, every regulatory su...

Use Journals & Congresses to sort over 10,000 journals and congresses by submission date and lead times. Get your answer quickly so you can focus on your work. See how easy it is for yourself & request a demo. https://ow...

Use Journals & Congresses to sort over 10,000 journals and congresses by submission date and lead times. Get your answer quickly so you can focus on your work. See how easy it is for yourself & request a demo. https://ow...

Biosimilars are gaining ground in APAC — but adoption depends on education. ICON’s latest blog dives into the real-world barriers to biosimilar uptake across Asia-Pacific, from low patient awareness to prescriber miscon...

Biosimilars are positively impacting healthcare in APAC — but awareness and trust remain critical hurdles. ICON explores how strategic education and engagement can unlock biosimilar adoption across Asia-Pacific, from em...

Recognising ICON’s Environmental, Social & Governance (ESG) commitment through our ICON Cares programme, we are honoured to be named one of the world’s best by TIME/ Statista. This list ranks the world’s 500 most sustain...

Recognising ICON’s Environmental, Social & Governance (ESG) commitment through our ICON Cares programme, we are honoured to be named one of the world’s best by TIME/ Statista. This list ranks the world’s 500 most susta...